4.59
前日終値:
$4.08
開ける:
$3.99
24時間の取引高:
90,925
Relative Volume:
0.62
時価総額:
$238.13M
収益:
$264.74M
当期純損益:
$-49.71M
株価収益率:
-1.1206
EPS:
-4.0959
ネットキャッシュフロー:
$-43.55M
1週間 パフォーマンス:
+2.23%
1か月 パフォーマンス:
+27.86%
6か月 パフォーマンス:
+201.97%
1年 パフォーマンス:
-4.97%
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
名前
Camp 4 Therapeutics Corp
セクター
電話
617-651-8867
住所
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CAMP
Camp 4 Therapeutics Corp
|
4.59 | 211.68M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 開始されました | Wedbush | Outperform |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | William Blair | Outperform |
| 2022-08-16 | アップグレード | Craig Hallum | Hold → Buy |
| 2021-12-22 | ダウングレード | Craig Hallum | Buy → Hold |
| 2021-09-24 | 繰り返されました | Craig Hallum | Buy |
| 2021-06-25 | 繰り返されました | Craig Hallum | Buy |
| 2020-12-18 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-04-17 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-05 | 繰り返されました | Craig Hallum | Buy |
| 2019-12-20 | 繰り返されました | Craig Hallum | Buy |
| 2019-12-20 | ダウングレード | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-01 | 繰り返されました | Craig Hallum | Buy |
| 2019-03-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-01-25 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-12-21 | アップグレード | Craig Hallum | Hold → Buy |
| 2018-12-14 | 繰り返されました | B. Riley FBR | Buy |
| 2018-12-11 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 開始されました | Goldman | Neutral |
| 2018-10-15 | 開始されました | Jefferies | Hold |
| 2018-09-28 | 繰り返されました | Craig Hallum | Hold |
| 2018-04-27 | 繰り返されました | Craig Hallum | Hold |
| 2018-03-08 | ダウングレード | Craig Hallum | Buy → Hold |
| 2018-02-16 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
すべてを表示
Camp 4 Therapeutics Corp (CAMP) 最新ニュース
Guidance Update: What is Camp4 Therapeutics Corporations book value per shareEarnings Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines - Traders Union
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment - Traders Union
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases - Traders Union
CAMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
RBOT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Camp4 Therapeutics Corp engages with SYNGAP1 community in Poland family day event - Traders Union
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Market Moves: Can AUUDW maintain its current growth rateEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CNTY PE Ratio & Valuation, Is CNTY Overvalued - Intellectia AI
How Camp4 Therapeutics Corporation stock reacts to job market dataMarket Sentiment Report & Weekly Chart Analysis and Guides - mfd.ru
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fed Meeting: Will Camp4 Therapeutics Corporation face regulatory challenges2025 Investor Takeaways & Low Volatility Stock Suggestions - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Risk Check: Is TACT undervalued by DCF analysisQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Is Camp4 Therapeutics Corporation stock a buy in volatile marketsJuly 2025 Update & Stepwise Trade Signal Implementation - mfd.ru
Is Camp4 Therapeutics Corporation being accumulated by smart money2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Can Camp4 Therapeutics Corporation ride the EV waveMarket Trend Review & Free Verified High Yield Trade Plans - mfd.ru
BRID PE Ratio & Valuation, Is BRID Overvalued - Intellectia AI
WRAP PE Ratio & Valuation, Is WRAP Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SY PE Ratio & Valuation, Is SY Overvalued - Intellectia AI
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
10 Best Online Therapy Platforms In 2026: Tested & Reviewed - Forbes
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
Downgrade Watch: Can Camp4 Therapeutics Corporation ride the EV waveTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Will Camp4 Therapeutics Corporation benefit from rising consumer demand2025 Sector Review & Verified Momentum Stock Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Cardiff Oncology (CRDF) - The Globe and Mail
Analysis Recap: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Retail Trends: Is CVD Equipment Corporation stock undervalued right nowExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Market Outlook: Will Camp4 Therapeutics Corporation stock benefit from M AJuly 2025 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Harbor Wellness Co. Partners with Fit Body Boot Camp for 4-Week Series on Injury Prevention and Proper Form - Sarasota Herald-Tribune
CAMP4 Therapeutics announces $28 million common stock offering - MSN
Signal Recap: Will Camp4 Therapeutics Corporation outperform the market in YEARMarket Growth Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
New CAMP4 hire receives option to buy 8,000 shares at $5.78 each in grant - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - sharewise.com
CAMP: CMP-002 targets SYNGAP1 disorders with first-in-class therapy, entering clinic this year - TradingView
Published on: 2026-01-10 23:34:38 - ulpravda.ru
CAMP4 Therapeutics updates corporate investor presentation materials - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking - Citeline News & Insights
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Stock Recap: What hedge fund activity signals for Camp4 Therapeutics Corporation stockMarket Performance Report & Verified Technical Signals - Улправда
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sandoz Group Ltd (OtherSDZXF) and Denali Therapeutics (DNLI) - The Globe and Mail
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wedbush Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
Insilico’s big gain after Hong Kong listing: Finance Report - biocentury.com
Camp 4 Therapeutics Corp (CAMP) 財務データ
収益
当期純利益
現金流量
EPS
Camp 4 Therapeutics Corp (CAMP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
大文字化:
|
ボリューム (24 時間):